| Ytd | 59.63% | |
| 1y | 190.36% |
| Open | 34.65 | Prev Close | 34.71 | Low | 34.02 | High | 35.34 | Mkt Cap | 25.02B |
| Vol | 39.47M | Avg Vol | 6.13M | EPS | -0.47 | P/E | N/A | Forward P/E | -20.17 |
| Beta | 1.13 | Short Ratio | 6.00 | Inst. Own | 78.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 35.15 | 200-d Avg | 28.21 | 1yr Est | 41.86 |
ROIV News
FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for De
Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its o
Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a 30-day supply
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy
The U.S. Food and Drug Administration said on Thursday it approved a treatment from Roivant and pa
BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV)
DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S.
DURHAM, N.C., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics announced today the publicatio
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auc
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raise
Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharm
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises th
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy
Roivant Sciences NASDAQ: ROIV said it expects a busy second half of 2026, with a potential launch of
Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.33 per share in line with the Zack
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analy
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' d
Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track f
CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is
California State Teachers Retirement System boosted its holdings in shares of Roivant Sciences Ltd.
Bank of Nova Scotia cut its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 7.9% during the first q
Allspring Global Investments Holdings LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ: RO
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV)
Roivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib.
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myosi
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises th
TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy
U.S. stocks halt a three-day slide as oil tumbles 5% on revived Iran truce hopes, easing inflation f
US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe'
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data s
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, unders
Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor c
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy
Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust l
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises th
Last week's top large-cap gainers surged on strong earnings beats and upbeat guidance (LITE, XPO
Roivant shares surged after its skin disease drug brepocitinib showed strong Phase 2 results, with h
The software-driven sell-off paused for a breather on Friday after eight straight sessions that had